sympathetic chain; and the ganglion cells of the gut. Thus, ALK is a novel orphan receptor tyrosine kinase that appears to play an important role in the normal development and function of the nervous system.
Anaplastic Lymphoma Kinase (ALK) was originally identi®ed as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused to nucleophosmin (NPM) in the t(2;5) chromosomal rearrangement associated with non-Hodgkin's lymphoma, but further insights into its normal structure and function are lacking. Here, we characterize a full-length normal human ALK cDNA and its product, and determine the pattern of expression of its murine homologue in embryonic and adult tissues as a ®rst step toward the functional assessment of the receptor. Analysis of the 6226 bp ALK cDNA identi®ed an open reading frame encoding a 1620-amino acid (aa) protein of predicted mass *177 kDa that is most closely related to leukocyte tyrosine kinase (LTK), the two exhibiting 57% aa identity and 71% similarity over their region of overlap. Biochemical analysis demonstrated that the *177 kDa ALK polypeptide core undergoes co-translational N-linked glycosylation, emerging in its mature form as a 200 kDa single chain receptor. Surface labeling studies indicated that the 200 kDa glycoprotein is exposed at the cell membrane, consistent with the prediction that ALK serves as the receptor for an unidenti®ed ligand(s). In situ hybridization studies revealed Alk expression beginning on embryonic day 11 and persisting into the neonatal and adult periods of development. Alk transcripts were con®ned to the nervous system and included several thalamic and hypothalamic nuclei; the trigeminal, facial, and acoustic cranial ganglia; the anterior horns of the spinal cord in the region of the developing motor neurons; the
Introduction
Diverse cellular processes such as division, differentiation, survival, metabolism, and motility can all be regulated through binding of cognate ligands to their speci®c receptor tyrosine kinases (RTKs) (reviewed in Schlessinger and Ullrich, 1992; Fantl et al., 1993) . The common structural features of the RTKs include an extracellular ligand-binding region, a hydrophobic membrane-spanning segment and a cytoplasmic domain that carries the catalytic function. In general, the activation of these molecules to initiate signal transduction involves ligand-mediated receptor dimerization and intermolecular transphosphorylation, which begins a phosphorylation cascade through the binding of SH2 or PTB domains of cellular substrates to speci®c receptor phosphotyrosine residues (Mayer and Baltimore, 1993; Schlessinger, 1994; van der Geer and Pawson, 1995) . Dysregulation of this process either at the level of the receptor or aecting key elements of the signaling cascade has been shown to result in a variety of neoplastic disorders or in altered development. For example, structural rearrangement of RTK genes, as seen with TRKA, MET and RET, has been shown to activate the transforming capacity of the proteins they encode, contributing to the genesis of human tumors (Martin-Zanca et al., 1986; Soman et al., 1991; Greco et al., 1992; Bongarzone et al., 1993) .
A number of studies have now demonstrated that RTKs normally function to regulate the cellular growth and dierentiation of speci®c tissues or organs. For example, the TRK gene family (TRK-A, -B and -C) encodes receptors for the neurotrophic ligands nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4 (Barbacid, 1993) . Targeting experiments in mice have demonstrated that functional inactivation of the TRK genes produces multiple abnormalities of the central and peripheral nervous systems (Snider, 1994) . The MET RTK has been shown to be the cell surface receptor for hepatocyte growth factor (HGF)/scatter factor (SF), which mediates liver development and regeneration (Bottaro et al., 1991; Naldini et al., 1991) and provides a signal for the migration of skeletal muscle precursor cells from the somites to the developing limbs and diaphragm (Bladt et al., 1995) . With increasing frequency, the normal functional role of RTKs is also being elucidated because of their identi®cation as disease genes. Recent examples include the identi®cation of RET mutations that lead to the loss of enteric innervation in Hirschsprung's disease (congenital megacolon) or to tumor formation in multiple endocrine neoplasia type IIB (van Heyningen, 1994) , and the causal association between mutations within ®broblast growth factor receptor (FGFR) family members and the congenital malformations Pfeier syndrome (craniosynostosis, cutaneous syndactyly and short, broad digits) (FGFR1) (Muenke et al., 1994) , Apert and Crouzon syndromes (craniosynostosis with or without syndactyly of the hands and feet) (FGFR2) (Wilkie et al., 1995) and achondroplasia (short-limbed dwar®sm and macrocephaly) (FGFR3) (Rousseau et al., 1994) .
We have recently described the positional cloning and characterization of the t(2;5)(p23;q35) chromosomal rearrangement found in approximately 10% of all non-Hodgkin's lymphomas (Morris et al., 1994) . This translocation produces a fusion gene that encodes a chimeric transforming protein comprised of the amino-terminal portion of the chromosome 5-encoded phosphoprotein nucleophosmin (NPM), a highly conserved RNA-binding nucleolar protein (Borer et al., 1989; Chan et al., 1989; Dumbar et al., 1993) , linked to the cytoplasmic portion of a novel receptor tyrosine kinase encoded on chromosome 2 which we named Anaplastic Lymphoma Kinase (ALK). Here, we describe the isolation and sequence analysis of a full-length normal human ALK receptor cDNA, demonstrating that ALK is a member of the insulin receptor subfamily of RTKs with closest homology to leukocyte tyrosine kinase (LTK) (Ben-Neriah and Bauskin, 1988; Bernards and de la Monte, 1990; Maru et al., 1990; Krolewski and Dalla-Favera, 1991; Snijders et al., 1993; Toyoshima et al., 1993; Kozutsumi et al., 1994) . Biochemical characterization of the ALK polypeptide encoded by this cDNA, and of the receptor protein produced endogenously by rhabdomyosarcoma skeletal muscle tumor cells, reveals that ALK is a large, glycosylated, single chain transmembrane receptor tyrosine kinase. In situ hybridization studies of mouse embryos and adult mouse organs indicate that the expression of the The transmembrane domain (residues 1031 ± 1058) is highlighted by a hatched box. Horizontal arrows¯ank the tyrosine kinase catalytic domain (residues 1123 ± 1376). The aminoterminal and carboxy-terminal extent of the overlap of the largest reported receptor isoform of human LTK (Toyoshima et al., 1993) with ALK is indicated. The position at which ALK is truncated by the t(2;5) to produce NPM-ALK is also shown (`NPM-ALK fusion junction ') homologue, Alk, is restricted to the nervous system, suggesting that the receptor binds a ligand(s) critical for neural development and function.
Results

Cloning and characterization of a full-length ALK cDNA
Analysis of a 6226 bp normal ALK cDNA (clone RMS17-2) isolated from a rhabdomyosarcoma library identi®ed an ATG codon at nucleotides 912 ± 914, followed by an open reading frame of 4857 bp and a 455 bp 3' untranslated region that terminated in a poly(A) tail. The nucleotide sequence surrounding the ATG encoding the presumed ALK initiator methionine (GGCGGGATGG) was in agreement with the consensus translation initiation sequence reported by Kozak 1987) and was preceded by two in-frame termination codons within 45 bp upstream of this site. The poly(A) tail of this insert was preceded, 20 bp upstream, by the canonical polyadenylation signal AATAAA. The 3' sequences of all ALK clones isolated (see Materials and methods) were identical to those present in the NPM-ALK fusion cDNA (Morris et al., 1994) , suggesting that mutations of the truncated receptor are not involved in activating the transforming potential of the chimera in non-Hodgkin's lymphoma. However, it should be noted that although we refer to the ALK cDNA reported here as encoding the`normal' full-length receptor, we cannot fully exclude the possibility that abnormalities of the receptor could be present in the ALK protein expressed by rhabdomyosarcoma tumor cells.
The long open reading frame following the initiator methionine of ALK encodes a polypeptide of 1620 amino acid residues with a molecular mass of 177,155 daltons ( Figure 1 ). The 26 amino-terminal residues of the ALK polypeptide comprise a highly hydrophobic stretch of amino acids representing a putative signal peptide sequence (von Heijne, 1986) . The predicted extracellular domain of ALK after signal peptide cleavage is 1004 amino acids long and is followed by 28 hydrophobic amino acids, consistent with a membrane-spanning segment. This single putative transmembrane domain is¯anked on its cytoplasmic side by basic amino acid residues typical of the junction between transmembrane and cytoplasmic domains (Blobel, 1980) . Within the extracellular portion of ALK are 16 consensus N-glycosylation sites (Asn-X-Ser/Thr), predicting that the mature ALK protein is glycosylated in vivo. The spacing of cysteine residues within the extracellular domains of receptor tyrosine kinases is thought to be important in determining ligand speci®city (Ullrich and Schlessinger, 1990) ; in its extracellular region, ALK contains 26 cysteine residues with two clusters residing between amino acids 425 and 487 (seven residues) and between amino acids 987 and 1021 (six residues). Consistent with the overall high degree of homology between ALK and LTK (see below), the spacing of all except the most N-terminal one of the 13 cysteine residues present in the overlapping extracellular portions of each of these proteins is conserved (Figure 2 ). The ALK juxtamembrane segment is of typical length (64 amino acids) and contains a NPXY motif (residues 1093 ± 1096, NPNY), which is found in the cytoplasmic portion of a number of cell surface proteins, including the low-density lipoprotein receptor and RTKs of the epidermal growth factor (EGF) and insulin receptor subfamilies, and is thought to be involved in ligandindependent receptor internalization within coated pits (Chen et al., 1990) . The NPXY motif has also recently been shown to mediate the interaction of RTKs with signaling substrates such as the insulin receptor substrate-1 (IRS-1) and Src homology and collagen (SHC) proteins through the substrate's phosphotyrosine binding (PTB) domain (van der Geer and Pawson, 1995) ; indeed, Fujimoto and colleagues have determined that the NPNY residues present in the juxtamembrane segment of the truncated and constitutively-activated ALK protein present in NPM-ALK mediate the association of the fusion protein with IRS- Figure 2 ALK is highly homologous to leukocyte tyrosine kinase (LTK). An amino acid sequence alignment of the extracellular, transmembrane and juxtamembrane segments of LTK with ALK is shown. Sequence identity is indicated by inverse lettering. This alignment was performed using the Genetics Computer Group, Inc. (GCG) BESTFIT program; amino acid similarity of greater (:) or lesser (.) degree was determined according to evolutionary distance as measured by Dayho and normalized by Gribskov Burgess (1986) . The LTK residues used for alignment are from the published sequence of the largest reported human receptor isoform (Toyoshima et al., 1993) ; (GenBank accession no. D16105). Within the region shown, ALK and LTK exhibit 48% amino acid identity and 63% similarity. The kinase and carboxy-terminal regions of ALK and LTK (not shown) are also highly related, sharing 64% and 44% identity, respectively 1 (Fujimoto et al., 1996) . The 254-amino acid ALK catalytic domain dontains the usual conserved motifs found in all protein tyrosine kinases and possesses paired tyrosine residues (ALK amino acids 1282 and 1283) characteristic of the major autophosphorylation site of the insulin receptor subfamily (Hanks et al., 1988) . The ALK carboxy-terminal tail is unusually long (244 amino acids), compared with that of other receptor kinases and, like the juxtamembrane and kinase domains, contains several potential phosphotyrosine residues that could serve as binding sites for substrates with SH2 or PTB domains (see Discussion).
Analysis of protein sequence databases con®rmed the identity of ALK as a member of the insulin receptor (IR) subfamily, with closest homology to the leukocyte tyrosine kinase (LTK) receptor (Ben-Neriah and Bauskin, 1988; Bernards and de la Monte, 1990; Maru et al., 1990; Krolewski and Dalla-Favera, 1991; Snijders et al., 1993; Toyoshima et al., 1993; Kozutsumi et al., 1994) . Within its kinase domain, ALK shares 64% residue identity with LTK, compared to 36% to 38% with IR subfamily members such as the TRK receptors, ROS, the insulin-like growth factor-1 receptor (IGF-1R), and the IR itself. Over their complete extent of overlap, ALK and the considerably smaller LTK (864 amino acids; Toyoshima et al., 1993) share 57% amino acid identity and 71% similarity. Only closely related RTKs exhibit sequence similarity in domains other than the kinase region; for example, in their extracellular region highly related RTKs such as the IR and the IGF-1R, the TRK receptors, and the EGF receptor and HER-2/ NEU have sequence identities on the order of 35% to 45% (Fantl et al., 1993) . Thus, the signi®cant relationship between ALK and LTK is even better illustrated by the observation that within their extracellular, transmembrane, and juxtamembrane regions, they exhibit 48% identity and 63% similarity (see Figure 2) , and over their carboxy-terminal tails they possess an identity of 44% and similarity of 59% within their region of overlap. Thus, based on their relatedness, it appears that ALK and LTK comprise an RTK subclass within the IR family similar to the IR/ IGF-1R, the TRK receptors, and the MET/RON/SEA receptor subgroups (Fantl et al., 1993; Hu et al., 1993; Gaudino et al., 1994) .
In our initial report of the positional cloning of NPM-ALK (Morris et al., 1994) , we incorrectly stated that sequences`from the extreme 5' ends of the ALK clones (referring to RMS4 and RMS17-2) were 50% identical to sequences encoding insulin-like growth factor binding protein (IBP-1)'. The alignments from which we drew this conclusion were performed using suboptimal sequence that was ultimately determined to be located within the 5' untranslated portion of ALK.
Comparison of the normal ALK amino acid sequence reported here with IBP-1 revealed no signi®cant homology between the two.
Biochemical characterization of ALK
In vitro transcription and translation of the ALK cDNA clone RMS17-2 yielded a single, prominent product whose migration in SDS ± PAGE under reducing conditions was consistent with the predicted molecular mass for the ALK polypeptide of 177 kDa (Figure 3 , lane 6); this protein was eciently immunoprecipitated by our polyclonal anti-ALK serum (not shown). To con®rm that the ALK cDNA which we had isolated encodes a full-length receptor, we subcloned the entire 6226 bp insert of RMS17-2 into the pcDNA3 mammalian expression vector (Invitrogen, San Diego, CA) for in vivo expression studies. The resulting plasmid, pcDNA3-ALK, was electroporated into COS-7 cells, which after 72 h were metabolically labeled with [ S-methionine-labeled cell lysates from COS-7 cells electroporated with the mammalian expression vector pcDNA3 (lane 1) or with a pcDNA3 construct containing the full-length ALK cDNA insert from clone RMS17-2 (lanes 2 and 3), and from the Rh30 cell line (lanes 4 and 5), were incubated with either preimmune (PI) or immune anti-ALK (I) serum. Immunoprecipitates were resolved by SDS ± PAGE on a 7.5% polyacrylamide gel under reducing conditions. The in vitro transcription/translation reaction product of ALK cDNA clone RMS17-2 was loaded directly and run in parallel on the same gel (lane 6). Note that the ALK cDNA product expressed in COS-7 cells appears to be correctly modi®ed in vivo and co-migrates with the endogenous Rh30 ALK receptor. The relative mobilities of the mature 200 kDa ALK glycoprotein (`gp200 ALK ') and the 177 kDa ALK polypeptide backbone (`p177 ALK ') are indicated rhabdomyosarcoma cell line (lane 5). This 200 kDa protein was not detected in COS-7 cells electroporated using`empty' pcDNA3 vector (lane 1), nor in control immunoprecipitations using preimmune serum (lanes 2 and 4).
The dierence in the size of the ALK protein that we identi®ed in vivo compared with the ALK product resulting from in vitro transcription/translation of the RMS17-2 clone suggested that post-translational modi®cations of the ALK polypeptide backbone occur during synthesis of the mature receptor. Since the deduced amino acid sequence of ALK contains multiple sites for potential N-linked glycosylation, we investigated whether the mature 200 kDa receptor is a glycoprotein by performing metabolic labeling experiments with the glycosylation inhibitor tunicamycin (Figure 4a ). Preincubation of Rh30 cells with a concentration of tunicamycin expected to totally inhibit glycosylation (25 mg/ml) revealed the presence of a single immunoreactive polypeptide (lane 3) identical in size to the 177 kDa in vitro transcription/translation product of the ALK cDNA (lane 1) (excluding the small size dierence due to the absence of the ALK signal sequence cleaved from the protein in vivo). Thus, it appears that the size dierence between the ALK polypeptide core and the mature receptor results from the addition of N-linked carbohydrate moieties. These data also indicate that ALK does not contain a signi®cant amount of O-linked glycosyl groups.
To further examine the in vivo processing of ALK, we performed a series of pulse-chase labeling experiments using Rh30 cells. Following incubation for 30 min in growth medium lacing methionine, the cells were pulse-labeled with [ 35 S]-methionine for 15 min, then chased with medium containing excess cold methionine and lysed for immunoprecipitation analysis at various time points. As illustrated in Figure 4b , glycosylated 200 kDa ALK protein was identi®ed even immediately after the end of the 15 min 35 S-methioninelabeling period (lane 3). Since no proteins of lower molecular mass were recognized by our polyclonal ALK antiserum, it is likely that nascent polysomebound ALK polypeptides become glycosylated during their synthesis while being transported into endoplasmic reticulum (ER). Further oligosaccharide processing of ALK presumably then occurs within The Golgi apparatus, before the protein is transported to the cell membrane (Kornfeld and Kornfeld, 1985) , resulting in a mature ALK glycoprotein of essentially the same molecular mass as the immature ER glycoprotein form, Cell lysates were immunoprecipitated with preimmune serum (PI) or polyclonal anti-ALK serum (`immune') and analysed by 6% polyacrylamide SDS ± PAGE under reducing conditions. The 177 kDa in vitro transcription/translation product of ALK cDNA RMS17-2 was run on the same gel for comparison although this supposition remains to be formally tested by analysis with inhibitors of ER/Golgi glycoprotein transport, oligosaccharide processing enzyme inhibitors, or speci®c glycosidases. Although the possibility exists that ALK could undergo a very prolonged ER/ Golgi transit period that exceeds the ®ve hour chase duration used in these studies, the production of lateappearing, Golgi-processed, glycosylated forms of the receptor that are of signi®cantly dierent molecular mass compared to the glycoprotein identi®ed in these 35 S-methionine-labeling experiments can be excluded because the approximately 200 kDa receptor was the only form of ALK identi®ed in cell surface labeling experiments (see Figure 6 ), immunocomplex kinase assays (Figure 7) , and anti-ALK immunoblots (not shown) that should detect steady-state levels of the mature, fully processed receptor.
Other receptors in the insulin RTK subfamily have been shown to possess varied structural characteristics of their mature forms, although each is initially translated as a single polypeptide produced from a single gene locus. For example, the insulin and insulin-like growth factor-1 receptors possess a disul®de-linked heterotetrameric a 2 b 2 structure, the MET and RON RTKs exist as ab disul®de-linked heterodimers, and the mature TRK RTKs (TRK-A, -B, and -C) are present in the cell membrane as monomeric proteins (Barbacid, 1993; Fantl et al., 1993; Gaudino et al., 1994) . As noted above, the ALK receptor immunoprecipitated in metabolic labeling studies from both COS-7 cells electroporated with the pcDNA3-ALK expression construct and from the Rh30 cell line is present as an apparently single prominent 200 kDa glycoprotein when analysed in SDS ± PAGE under reducing conditions; no larger precursor molecules that might subsequently be post-translationally cleaved into subunit proteins, nor smaller bands that could represent subunit fragments that are normally linked via disul®de bonds, were seen in either steady-state (Figures 3 and 4a ) or pulse-chase labeling studies (Figure 4b ). Further evidence that the mature ALK receptor does not possess a disul®de-linked multi-subunit structure (as found with the IR, IGF-1R, MET and RON RTKs) was provided in metabolic labeling experiments in which the ALK receptor observed under non-reducing conditions co-migrated with the 200 kDa glycoprotein identi®ed in the reduced state ( Figure 5 ). These observations indicate that, like the TRK RTKs, ALK exists in its mature form as a single chain receptor with, based upon its deduced amino acid sequence, a single transmembrane segment.
To provide biochemical evidence for the hypothesis that ALK encodes a membrane-spanning receptor, we performed biotinylation studies with COS-7 cells that had been electroporated with pcDNA3-ALK to selectively label cell surface proteins. Intact COS-7 cells in tissue culture dishes were incubated with biotin-CNHS-ester using conditions previously shown to label cell surface-exposed proteins only (Meier et al., 1992) , the biotinylation reaction quenched and the cells lysed. As shown in Figure 6 , immunoprecipitation of the lysates prepared from these cells using polyclonal ALK antibody readily detected the mature 200 kDa ALK glycoprotein, indicating that the ALK receptor encoded by our cDNA is correctly inserted into the cell membrane, with exposure of the putative ligandbinding domain extracellularly.
Activation , 1990) . This process can be mimicked by receptor-speci®c bivalent antibody, as has been demonstrated in in vitro immunocomplex kinase assays for a number of RTKs. To determine whether the ALK protein encoded by our cDNA is indeed a functional kinase, we incubated recombinant gp200 ALK immunoprecipitated from COS-7 cells with [g- 
Phosphoamino acid analysis demonstrated that the in vitro autophosphorylation of ALK was restricted to tyrosine residues (Figure 7b ). Sequential anti-ALK immunoprecipitation/anti-phosphotyrosine immunoblotting of lysates prepared from NIH3T3 cells stably expressing our transfected cDNA and from Rh30 cells revealed no evidence of in vivo autophosphorylation of the receptor, suggesting that no activating mutations are present in the ALK rhabdomyosarcoma cDNA that we have isolated nor is there an autocrine loop present in the cells (not shown).
Analysis of the expression of the mouse homologue Alk by in situ hybridization
As an initial step to elucidate the normal functions of the receptor, we performed Alk in situ hybridization studies on adult mouse tissues as well as mouse embryos ranging in age from day 10 postconception to 4 days postpartum. No signal was detected in the day-10 embryos. After day 10, the in situ results indicated that Alk transcripts are restricted to the central and peripheral nervous systems. In day 11 embryos, signal was detected in the ventral aspect of the primitive spinal cord and in the developing trigeminal and facial ganglia (not shown). By day 12, there was additional expression in the periventricular zone around the third ventricle; although the primitive neuroepithelial cells in this region were generally negative, one focal area in this zone showed positive cells in the region of the cerebral aqueduct (not shown). In later stages of embryonic development, the expression pattern of Alk became more evident in the developing thalamic nuclei and other nuclear groups surrounding the third ventricle. The complex pattern of positive signals illustrated in P]ATP and analysed by 7.5% polyacrylamide SDS ± PAGE performed under reducing conditions as described in the Materials and methods. A one minute autoradiographic exposure performed at room temperature is shown. The identity of the two phosphorylated proteins with faster mobility relative to p75 NPM ± ALK is unknown but they may represent NPM ± ALK proteolytic degradation fragments and/or proteins that are known to be associated with, and phosphorylated by, NPM-ALK such as SHC (Fujimoto et al., 1996; Bischof et al., in press ). (b) In vitro phosphorylated gp200 ALK was cut from the polyacrylamide gel and eluted, and its phosphoamino acid composition determined by two-dimensional thin-layer electrophoresis. pS, phosphoserine; pT, phosphothreonine; pY, phosphotyrosine. The sample origin, as well as partially hydrolyzed peptides that run near the origin, are not illustrated but were located toward the lower righthand portion relative to the ®gure; the directions of electrophoresis and their pH are as indicated COS-7/ pcDNA3-ALK Figure 6 Exposure of gp200 ALK at the cell surface. Intact COS-7 cells previously electroporated with either the pcDNA3 mammalian expression vector alone (lane 1), or a pcDNA3 construct containing the RMS17-2 ALK cDNA (lanes 2 and 3), were surface-labeled by biotinylation and the cells lysed in RIPA buer subsequent to quenching of the labeling reaction. The lysates were incubated with preimmune (PI) or anti-ALK (I) serum, proteins were resolved by 7.5% polyacrylamide SDS ± PAGE, transferred to a PVDF membrane, and detected by chemiluminescence as described in Materials and methods discrete populations of primitive neuronal cells clustered around the third ventricle. Intense signal was also identi®ed in the region of the developing olfactory nerves as they course through the area of the nasal cavity. Regardless of the developmental stage, Alk transcripts could not be detected in the outer cortical layers, basal ganglia, cerebellum, choroid plexus, or ependymal lining. The spinal cord in the day-14 embryo continued to show expression in the developing ventral horns, whereas no expression was identi®ed in the spinal ganglia (Figure 8d ). Day 15-16 and older embryos continued to show expression in the brain primarily in the region of the thalamic nuclei, as well as in cranial ganglia, the sympathetic chain, and the ventral spinal cord (Figure 8e-g ).
Alk expression was not detected at any developmental stage in any non-neural tissues, including the liver, lungs, thymus, kidney, adrenal glands, pancreas, connective tissue, muscle, or bone. Occasional bands of intense signal were observed in the pelvic region, extremities, tongue, and facial region, which we interpret to represent developing peripheral nerves. Newborn and adult mouse brain also exhibited Alk expression restricted predominantly to the thalamic region ( Figure 8h ). Signal was also detected in the hypothalamic region, but the basal ganglia, cerebellum, and cortex continued to show no signi®cant Alk expression. Finally, the peripheral enteric nervous system also showed evidence of Alk transcripts in both the embryo and adult as shown in Figure 8i-j) , which illustrate expression in the ganglion cell population of the stomach wall.
Discussion
The results of our analysis indicate that ALK is most similar to members of the insulin receptor (IR) subfamily of receptor tyrosine kinases. For example, its putative autophosphorylation sites (tyrosine residues 1282 and 1283) are of the`YY' motif characteristic of the kinases that belong to this subfamily (Hanks et al., 1988) , and its homology to the previously described subfamily member leukocyte tyrosine kinase (LTK) is quite striking (Figure 2 ). The relatedness of ALK and LTK (57% identity and 71% amino acid similarity over their entire region of overlap) indicates that these two proteins have likely evolved from a common ancestral gene; together, they appear to constitute an IR family subclass analogous to the IR/IGF-IR, the TRK receptors and MET/RON/SEA (Fantl et al., 1993; Hu et al., 1993; Gaudino et al., 1994) . Although initially reported as a transmembrane protein devoid of an extracellular domain (Ben-Neriah and Bauskin, 1988), LTK cDNA clones encoding two forms of a more typical receptor tyrosine kinase have more recently been characterized (Krolewski and DallaFavera, 1991; Snijders et al., 1993; Toyoshima et al., 1993) . In addition, other LTK cDNAs containing alternatively spliced exons that disrupt the open reading frame of the receptor form of the protein have been isolated and predict a soluble receptor devoid of both the transmembrane and tyrosine kinase domains as well as a membrane-spanning receptor that lacks the catalytic domain (Toyoshima et al., 1993) . Unfortunately, the determination of the functional importance of these various predicted LTK proteins, as well as the elucidation of the normal function of LTK in growth and development in general, has been hindered because of the inability of a number of laboratories to readily detect in vivo expression of endogenous LTK in any tissue except by immunostaining of sections, apparently because of low expression levels (Bernards and de la Monte, 1990; Krolewski and Dalla-Favera, 1991; Toyoshima et al., 1993) . The ALK cDNA which we have characterized contains in its extracellular domain residues corresponding to the largest LTK receptor isoform (Snijders et al., 1993; Toyoshima et al., 1993) , including amino acids encoded by an alternatively spliced LTK exon (homologous to ALK residues 878 ± 939). The region of overlap in the extracellular domains of ALK and LTK contains no immunoglobulin loop or ®bronectin type III repeat motifs as are commonly found in the extracellular segments of some receptor tyrosine kinases (Fantl et al., 1993) . A striking feature of this region, but one of uncertain signi®cance, is the conservation between the two proteins of several short glycine-rich segments (Figure 2 ). These segments bear some resemblance to the usually more extensive glycine-rich regions that are found in some structural proteins of the epidermis (e.g., loricrin and keratins 1 and 10) (Steinert et al., 1985; Zhou et al., 1988; Hohl et al., 1991) , a number of RNA-binding proteins (Burd and Dreyfuss, 1994) , and certain plant cell wall proteins (Condit and Meagher, 1986) and that are predicted to convey¯exibility to the supramolecular structure of the proteins containing them. Whereas LTK mRNA transcripts are normally expressed in neuronal cells, placenta, pre-B lymphocytes, and some mature B and T cells (Ben-Neriah and Bauskin, 1988; Bernards and de la Monte, 1990; Maru et al., 1990) , ALK is not normally expressed in hematopoietic cells. Given the high degree of similarity between ALK and LTK, we suggest that the constitutively activated cytoplasmic portion of ALK present in NPM-ALK in t(2;5) ± positive lymphomas may signal via LTK pathway substrates to transform lymphocytes.
We have previously shown by Northern analysis that in addition to human mRNA transcripts of roughly 6.5 kb (presumably corresponding to the cDNA described here), an 8.0 kb ALK message is expressed in rhabdomyosarcoma, small intestine (in the enteric innervation), and brain (Morris et al., 1994) . No variant cDNA clones potentially representing the 8.0 kb ALK transcript were isolated in our screening of two human rhabdomyosarcoma cDNA libraries, perhaps because this transcript is signi®cantly less abundant than the approximately 6.5 kb message. In our prior studies, we also identi®ed ALK messages of approximately 6.0 kb in human testis, placenta, and fetal liver and a 4.4 kb transcript unique to testis (Morris et al., 1994) . Interestingly our mouse in situ hybridizations, performed with an Alk juxtamembrane probe that is 96% nucleotide identical to the corresponding human ALK segment and that hybridizes to these non-neural human ALK transcripts in Northern blots (SW Morris, unpublished data), failed to identify Alk expression in mouse testis or fetal liver (mouse placenta was not examined). Hybridization of this probe to an adult mouse tissue Northern blot containing mRNA from heart, brain, spleen, lung, liver, skeletal muscle, kidney and testis (Multiple Tissue Northern blot no 7762-1, Clontech, Palo Alta, CA) revealed very weak expression of Alk limited to the brain (not shown). It is possible that the human 4.4 kb and 6.0 kb ALK transcripts may serve a function(s) unique to the tissues in which they are found. We are currently attempting to isolate and characterize clones corresponding to these transcripts using PCR, as well as conventional hybridization, screening of appropriate cDNA libraries. These dierent transcripts may, of course, result from alternative transcriptional start sites and/or polyadenylation signals; however, given the homology between ALK and LTK, and the demonstration of the extensive alternative splicing of LTK, it is tempting to speculate that ALK messages encoding human tissue-speci®c receptor isoforms could exist. The generation by dierential splicing of soluble receptors (Johnson et al., 1990; Petch et al., 1990; Werner et al., 1992) , membrane-bound receptors lacking their catalytic domain (Prat et al., 1991; Barbacid, 1993) , or tissue-speci®c receptor forms possessing dierent ligand-binding and biological activities (Miki et al., 1992; Werner et al., 1992) has been demonstrated for various RTKs. Interestingly, recent immunostaining studies of normal human tissues using an anti-ALK monoclonal antibody generated against cytoplasmic residues 1359 ± 1460 of the human receptor identi®ed weak ALK protein expression restricted to the nervous system, with no apparent expression in testis, placenta or fetal liver .
The cytoplasmic molecules that mediate downstream signaling by ALK are presently incompletely known. A number of receptor tyrosine kinase substrates are known to interact with activated receptors through their SRC homology region 2 (SH2) domains, binding to a speci®c phosphotyrosine residue contained within a distinct amino acid sequence of the receptor. That speci®c phosphotyrosine-containing sequences bind to a given substrate SH2 domain has now been con®rmed for several signaling molecules by mutational studies, including phosphatidylinositol 3-kinase (PI3-K), Ras GTPase-activating protein (RasGAP), phosphoinositide-speci®c phospholipase C-type g (PLC-g), and growth factor receptor-bound substrate 2 (GRB-2), among others (Pawson and Gish, 1992; Mayer and Baltimore, 1993) . Furthermore, the consensus sequence motifs recognized by the SH2 domains of most of the other known receptor tyrosine kinase substrates have been predicted based upon techniques using degenerate phosphopeptide libraries (Zhou et al., 1993; Songyang et al., 1994) . Analysis of the amino acid sequence of the cytoplasmic portion of ALK reveals potential sites for interaction with the SH2 domains of PI3-K (YXXM; ALK residues 1359 ± 1362, YRIM), RasGAP (YMPX; ALK residues 1327 ± 1330, YMPY), and PLC-g (E/IXXXXY; ALK residues 1277 ± 1282, IYRASY and 1322 ± 1327, IFSLGY). In addition, ALK contains two NPXY motifs (residues 1093 ± 1096, NPNY and 1504 ± 1507, NPTY) which have been shown to mediate the binding of the substrates SHC and IRS-1 to receptor tyrosine kinases via the substrate phosphotyrosine-binding (PTB) domain (or more correctly in the case of IRS-1, a PTB-like domain). The PTB domain is a recently described non-SH2 motif also capable of speci®cally binding phosphotyrosinecontaining peptides (van der Geer and Pawson, 1995). Although we have not yet analysed the role of various RTK substrates in the ALK signal transduction pathway, we have performed co-immunoprecipitation studies of the constitutively active NPM-ALK fusion protein and the substrates PI3-K, PLC-g, and SHC in the t(2;5)-positive lymphoma cell line SUP-M2; each of these signaling molecules is physically associated with NPM-ALK, which contains the entire cytoplasmic portion found in the normal receptor (Bischof et al., in press, and SW Morris, manuscript submitted). It is therefore likely that the normal ALK receptor signals in part via these substrates. In a recently published report Fujimoto and colleagues addressed the role of IRS-1 and SHC in NPM-ALK-mediated NIH3T3 ®broblast transformation by using mutant constructs in which one or both tyrosine residues within the two ALK NPXY motifs were changed to phenylalanine (Fujimoto et al., 1996) . In these experiments, IRS-1 was shown to bind to the phosphorylated NPM-ALK tyrosine residue 156 (corresponding to ALK residue 1096) whereas SHC bound NPM-ALK phosphotyrosine 567 (corresponding to residue 1507 of the normal receptor). Interestingly, both of the single point mutant chimeras, as well as a double mutant that was unable to bind either IRS-1 or SHC, transformed NIH3T3 eciently, indicating that neither substrate is essential for the oncogenic conversion of ®broblasts by NPM-ALK. In addition, all three point mutant chimeras were demonstrated to eciently interact with GRB2 despite the absence in NPM-ALK of a consensus GRB2 binding site. We have also examined the interaction of SHC with NPM-ALK in studies using an engineered mutant,
DC154
NPM-ALK, that lacks its carboxy-terminal 154 residues, including the NPTY motif at residues 564 ± 567 (Bischof et al., in press) . In agreement with the data of Fujimoto and co-workers, DC154 NPM-ALK was unable to interact with SHC. In addition, despite its large carboxy-terminal deletion, this NPM-ALK mutant protein transformed rodent ®broblasts almost as eciently as the wild-type fusion protein. In related studies, we have also demonstrated that wild-type NPM-ALK can render the IL-3 dependent cell line 32D factor-independent (SW Morris, unpublished data). Because these mouse myeloid cells express neither IRS-1, nor the IRS-1 related molecule 4PS (Wang et al., 1993) , it can be inferred that cytoplasmic signaling by normal ALK may not require these substrates. Lastly, it should also be noted that the cytoplasmic region of ALK contains several possible tyrosine phosphorylation sites that reside in motifs dierent from already described SH2 or PTB domain binding sequences, suggesting that the receptor may bind novel RTK substrates or bind known substrates through unique motifs.
We demonstrate here that the expression of the mouse homologue Alk appears to be restricted to neural tissue. Although we have not as of yet analysed the expression of the Alk protein in the mouse, we have demonstrated in immunostaining studies of normal adult human tissues that ALK is restricted to the nervous system and is present at low levels . These studies identi®ed weak labeling with an ALK monoclonal antibody of some endothelial cells, pericytes, and scattered glial cells in the hypothalamus, basal ganglia, cerebral cortex, and cerebellum. Low level expression of ALK was also noted in scattered neuronal cells in the hypothalamus, thalamic nuclei and basal ganglia. The pattern of Alk mRNA expression within the central nervous system appears to be essentially non-overlapping with that of Ltk, which is expressed in post-term and adult cerebral cortex and hippocampus, but not in embryonic mouse brain (Bernards and de la Monte, 1990) . Alk shares a partially overlapping expression pattern with the genes encoding the Trk family of neurotrophin receptors, the Trk-C expression pattern being most similar (with expression in the spinal cord and enteric nervous system like Alk), but still with substantial dierences both temporally and spatially (Klein et al., 1990; Martin-Zanca et al., 1990; Barbacid, 1993; Lamballe et al., 1994) . Our data raise the possibility that Alk could bind one of the identi®ed neurotrophins (nerve growth factor, brainderived neurotrophic factor, neurotrophin-3, or neurotrophin-4) or a novel neurotrophic ligand. Chemical cross-linking studies using radioiodinated preparations of the known neurotrophins to examine receptor expression in protein lysates prepared from mouse and chicken neuronal tissues have failed to identify ligand-receptor complexes of the greater than 200 kDa size that would be expected based on our analysis of the mature human ALK receptor, lending support for the interaction of the receptor with a novel factor (Escandon et al., 1994) . In addition, the extracellular portion of ALK shows minimal homology with the TRK family receptors and contains a dierent pattern of cysteine residue spacing, suggesting dierent ligand speci®cities. Our in situ hybridization results suggest that the human ALK transcripts that we have previously identi®ed by Northern analysis in small intestine, and that are also weakly present in colon and prostate (Morris et al., 1994) , most probably re¯ect ALK transcription in the neural structures supplying these tissues as opposed to the tissue parenchyma itself. Additional examination of the expression of ALK transcripts in speci®c human tissues, as well as the phenotypic analysis of mice lacking functional Alk receptors, both currently in progress, should help to more fully elucidate the role of this RTK in mammalian development and growth.
Materials and methods
Isolation and nucleotide sequencing of ALK cDNA clones
As we have previously reported, ALK transcripts of approximately 6.5 and 8.0 kb are expressed at moderately abundant levels in cell lines derived from the skeletal muscle tumor rhabdomyosarcoma (Morris et al., 1994) . To isolate normal ALK cDNA clones, we screened two cDNA libraries (made with either oligo(dT) or random hexamer primers for ®rst-strand synthesis) that had been prepared with poly(A) + RNA from the rhabdomyosarcoma line Rh30 (Shapiro et al., 1993) . Initial screens, performed with a 1.27 kb SacI cDNA fragment from the 3' portion of the NPM ± ALK cDNA (previously designated pS1.2) (Morris et al., 1994) , yielded seven overlapping clones, including three with inserts larger than 4.5 kb (clones RMS 1, 4 and 17-2), from the oligo(dT)-primed library. The largest insert (6226 bp from clone RMS17-2) was sequenced in its entirety. The nucleotide sequence of the other two large insert clones was determined partially and was identical to that of RMS17-2. The insert of the largest clone (RMS15-3, insert size-3.5 kb) isolated by screening the randomprimed Rh30 library with a 1.94 kb SacI ALK cDNA fragment (designated pS1.9) that is located immediately upstream of pS1.2 was sequenced completely, and was also found to be identical in its region of overlap (the most 5' extent of the full-length cDNA) to the RMS17-2 nucleotide sequence.
Double-stranded DNA templates were sequenced using dye-terminators and Taq sequencing methods, as recommended by the manufacturer (Perkin Elmer/Applied Biosystems, Inc. [PE/ABI], Norwalk, CT). Samples were electrophoresed and analysed on PE/ABI 373 and 373 Stretch DNA sequencers. Contig assembly was performed using Staden's X-windows software, and the consensus sequence was analyzed using the Wisconsin Package v. 8.0 software (Genetics Computer Group, Inc., Madison, WI) and National Center for Biotechnology resources (BLAST, FARFETCH, etc.).
Construction and analysis of an ALK expression plasmid
The complete 6226 bp SalI/NotI ALK cDNA insert from RMS17-2 was subcloned into the EcoRV/NotI-digested CMV promoter-based mammalian expression vector pcDNA3 (Invitrogen, San Diego, CA) following Klenow polymerase ®ll-in of the SalI overhang. In vitro transcription and translation with this construct was performed using the T N T coupled reticulocyte lysate system (Promega, Madison, WI) and T7 polymerase. Transient expression studies of this ALK plasmid and pcDNA3`empty' vector (as a negative control) in COS-7 monkey kidney epithelial cells were performed by electroporation in 0.4 cm cuvettes (960 mF, 250V). Cells were used for experiments at 72 ± 96 h post-electroporation.
Preparation of ALK-speci®c antiserum
An immunogen for ALK antibody production was prepared by ligating a 303 bp AccI/PstI ALK cDNA fragment that encodes residues 1359 ± 1460 of the protein (corresponding to residues 419 ± 520 of the chimeric NPM-ALK protein) in-frame into the pQE bacterial expression vector (QIAexpress Expression System, Qiagen, Chatsworth, CA) to produce an ALK polypeptide containing an amino-terminal tag of six consecutive histidine residues for binding to nickel-nitriloacetic acid agarose. This protein was expressed in the M15[pREP4] E coli strain and puri®ed by metal chelate anity chromatography as per the manufacturer's instructions, then used to immunize rabbits. The resulting polyclonal ALK antibody (designated`anti-ALK #11') was used in all protein studies. Serum from rabbits bled prior to immunization was used for preimmune controls.
Protein studies
Lysates from metabolically labeled cells and from cells analysed in surface biotinylation experiments were prepared using radioimmunoprecipitation assay (RIPA) buer (150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris, pH 7.2) containing 0.5% aprotinin, 1 mM PMSF, 2 mM EDTA, and 1 mM Na 3 VO 4 . Cell lysates were clari®ed of insolubles by a 2 min centrifugation at 14 000 RPM in a microfuge, then incubated for 2 h at 48C with a 1 : 100 dilution of either preimmune serum or anti-ALK rabbit serum. Immunoprecipitates were collected after a 1 h incubation at 48C with 40 ml of a 1 : 1 (vol:vol) slurry of protein A-Sepharose (CL-4B; Pharmacia, Piscataway, NJ) in phosphate-buered saline, and were extensively washed with RIPA buer before suspension in Laemmli's sample buer, with or without 5% 2-mercaptoethanol. The protein samples were then analysed by sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS ± PAGE) on 6% or 7.5% polyacrylamide gels. Cells were metabolically labeled with [
35 S]-methionine (100 mCi/ml; 41000 Ci/ mmol; Amersham, Arlington Heights, IL) for 2 h at 378C in methionine-free DMEM containing 5% dialyzed fetal calf serum (Gibco BRL, Gaithersburg, MD), following a 30 min preincubation in the same medium without added radioactive methionine. N-linked glycosylation was inhibited by treating the cells with tunicamycin (Sigma, St. Louis, MO; 25 mg/ml of medium) during both the preincubation and labeling periods. For pulse-chase experiments, cells were preincubated in methionine-free DMEM containing 5% dialyzed FCS for 45 min at 378C, labeled for 15 min with 200 mCi [ 35 S]-methionine per ml of media, and chased for the indicated intervals in DMEM containing 10% fetal calf serum and 30 mg liter cold Lmethionine.
Biotinylation of cell surface proteins was performed as previously described (Meier et al., 1992) , with only minor modi®cations. Brie¯y, cells were washed twice with warm phosphate-buered saline, once at room temperature in biotinylation buer (10 mM Na borate, pH 8.8, 150 mM NaCl), and then incubated for 15 min at room temperature in biotinylation buer containing 50 mg/ml D-biotinyl-Saminocaproic acid N-hydroxysuccinimide ester (biotin-CNHS-ester) (Boehringer-Mannheim, Indianapolis, IN). The labeling reaction was stopped by adding NH 4 Cl to a ®nal concentration of 10 mM and washing the cells extensively in wash buer (50 mM Tris-HCl, pH 7.4, 25 mM KCl, 5 mM MgCl 2 , and 1 mM EGTA) prior to lysis in RIPA buer. Immunoprecipitations were performed exactly as detailed above, except that lysates were pre-cleared prior to the addition of preimmune or immune serum by incubation with 40 ml of 1 : 1 protein A-Sepharose : phosphate-buered saline for 2 h at 48C. Proteins were resolved by 7.5% SDS ± PAGE and transferred to polyvinylidene di¯uoride (PVDF) membrane ®lters (Immobilon-P, Millipore, Bedford, MA) using a semidry blotting system (SemiPhor Transfer Unit, Hoefer Scienti®c Instruments, San Francisco, CA). PVDF membranes were incubated for 1 h at room temperature in blocking reagent (PBS containing 0.1% Tween-20 and 3% nonfat dry milk), followed by three 15 min room temperature washes with PBS containing 0.1% Tween-20. The membranes were incubated in streptavidin-biotin-horseradish peroxidase complex diluted 1 : 100 in PBS containing 0.1% Tween-20 for 1 h at room temperature, then washed in PBS and 0.1% Tween-20 ®ve times for 15 min each; the biotinylated proteins were detected by enhanced chemiluminescence (ECL kit, Amersham).
For in vitro kinase assays, cells were lysed in NP-40 lysis buer (1% NP-40, 150 mM NaCl, 25 mM Tris, pH 7.4) containing protease inhibitors and Na 3 VO 4 in concentrations identical to those noted above. Immunocomplexes were washed three times in this buer and twice in kinase buer (25 mM HEPES, pH 7.4, 12.5 mM MnCl 2 . 6.5 mM MgCl 2 prior to resuspension in 10 ml kinase buer containing 20 mCi of [g-32 P]ATP (6000 Ci/mM, Dupont NEN, Boston, MA) and 0.1 mM Na 3 VO 4 . Reactions were performed at 378C for 30 min, and stopped by boiling in the presence of 10 ml of 26 Laemmli's sample buer, prior to SDS ± PAGE on 7.5% polyacrylamide gels. Phosphoamino acid analysis of in vitro g-32 P ATP-labeled ALK was carried out as previously described (Shih et al., 1982) . Brie¯y, labeled ALK protein was eluted from the gel, extensively digested with TPCKtrypsin, and hydrolyzed in 6 N HCl for 1 h at 1008C. Following lyophilization, phosphoamino acids were resolved by thin-layer electrophoresis in two dimensions (pH 1.9 followed by pH 3.5).
In situ hybridization
An Alk in situ hybridization probe was prepared by polymerase chain reaction ampli®cation of the 187-bp exon that encodes the juxtamembrane segment of the receptor with a genomic mouse Alk clone that had been previously used for chromosomal localization of the gene in the mouse (Mathew et al., 1995) as a template and the primers JM Alk A GC (5'-CACCTATCTGTCTAGAGTGTACCGTCGGAAG-3') and JM Alk B A G (5'-CAGTAGCAGGTACCCTCACCGGATGAGTGTGATG-3') which are homologous or reverse complementary, respectively, to exon and intron sequences spanning the 5' or 3' boundaries of the exon. This probe produces a single-copy gene pattern in Southern hybridizations of mouse genomic DNA performed at low stringency (SW Morris, unpublished data) and, thus, is unlikely to cross-hybridize under the in situ hybridization conditions used with the mRNAs of other potentially related genes. Restriction enzyme recognition sites for XbaI (JM Alk A) or KpnI (JM Alk B) were engineered into the primers as shown above (altered nucleotides are italicized, with the correct sequence indicated above each) to facilitate subcloning into pBluescript SK + (Stratagene). Digestion with XbaI and transcription with T7 RNA polymerase were used to produce the antisense probe, while KpnI digestion and T3 RNA polymerase generated the negative control sense probe.
Embryos were harvested at various stages of gestation, ®xed in 4% paraformaldehyde overnight at 48C, soaked in 30% sucrose, and embedded in M1 freezing media and frozen in liquid nitrogen.
35
S-labeled UTP sense and antisense riboprobes to detect Alk mRNA transcripts were labeled and hybridized as previously described (Witte et al., 1993) on cryostat sections overnight at 458C with 1610 6 counts per min of radiolabeled probe. Following hybridization, sections were treated with 50 mg/ml of RNAase A (Sigma) and 100 units/ml of RNAase T1 (Boehringer-Mannheim). The RNAase-treated sections were then washed in 50% formamide, 26SSC and 20 mM DTT at 558C for 60 min. Following the formamide wash, sections were washed in a descending series of SSC solutions to a ®nal stringency of 0.16SSC at 508C. After dehydration in alcohol, slides were dipped in NTB 2 emulsion (Kodak) and exposed for periods ranging from 2 ± 4 weeks at 48C. Hybridization signal was visualized after developing the emulsion-coated slides with Kodak D19 developer at 168C. All sections were counterstained in hematoxylin and eosin and photographed under dark-and bright-®eld illumination.
Nucleotide sequence accession number
The nucleotide sequence of human ALK cDNA clone RMS17-2 has been entered in GenBank under accession number U62540.
